

#5

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 5882-66-BD	SERIAL NO. 09/980,540
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT BERNARD GAUDILLIERE, ET AL.	
		FILING DATE OCTOBER 25, 2001	GROUP 1614/624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
B.K. 1 5 8 5 4 9	19.01.83	Germany (EAST)			x

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

B.K.	Beavo and Reifsnnyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", <u>Trends Pharmacol. Sci. ("TIPS")</u> , Vol. 11, 1990, pages 150-155
	Beavo et al., "Multiple Cyclic Nucleotide Phosphodiesterases", <u>Molecular Pharmacol.</u> , Vol. 46, 1994, pages 399-405
	Doherty, "Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents", <u>Current Opinion Chemical Biology</u> , Vol. 3, 1999, pages 466-473
	Mohammed and Young, "Clinical aspects and treatment of chronic obstructive pulmonary disease", <u>Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs</u> , Vol. 1, No. 1, 1999, pages 21-28
	Schmidt et al., "Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease", <u>Clin. Exp. Allergy</u> , Vol. 29, Suppl. 2, 1999, pages 99-109
	Nieman et al., "SB 207499 (Ariflo™), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma", <u>American Journal of Respiratory and Critical Care Medicine</u> , Vol. 157, No. 3, 1998, page A413
	Underwood et al., "The second generation phosphodiesterase (PDE)4 inhibitor, SB 207499, inhibits antigen-induced bronchoconstriction and eosinophilia and LPS-induced airway neutrophilia and edema in the guinea pig", <u>Eur. Respir. J.</u> , Vol. 12, 1998, abstract no. P663, page 86s
	Compton et al., "Ariflo™ (SB 207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD", <u>American Journal of Respiratory and Critical Care Medicine</u> , Vol. 159, No. 3, 1999, page A522
	Murdoch et al., "The safety and tolerability of Ariflo™ (SB 207499), a novel & selective phosphodiesterase 4 inhibitor, in healthy male volunteers", <u>American Journal of Respiratory and Critical Care Medicine</u> , Vol. 157, No. 3, 1998, page A409
	Yoshihiro Waki et al., "Effects of XT-44, a Phosphodiesterase 4 Inhibitor, in Osteoblastogenesis and Osteoclastogenesis in Culture and Its Therapeutic Effects in Rat Osteopenia Models", <u>Jpn. J. Pharmacol.</u> , Vol. 79, 1999, pages 477-483

EXAMINER <i>B.K.</i>	DATE CONSIDERED 2/15/03
-------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF
COMMERCE PATENT AND
TRADEMARK OFFICEATTY. DOCKET NO.
5882-66-BDSERIAL NO.
09/980,540SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
BERNARD GAUDILLIERE, ET AL.FILING DATE
OCTOBER 25, 2001GROUP
~~1614~~ 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

B.K.		Ram and Srimal, "Synthesis of [1,2,4]-Triazoloquinazolinones and Related Compounds as Antihypertensive Agents", <u>J. Prakt. Chem.</u> , Vol. 332, No. 5, 1990, pages 629-639
		Burnouf et al., "Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]-diazepino[6,7,1- <i>hi</i>]indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors", <u>J. Med. Chem.</u> , Vol. 43, No. 25, 2000, pages 4850-4867
		Barnes, "Chronic obstructive pulmonary disease: new opportunities for drug development", <u>Trends Pharmacol. Sci. ("TIPS")</u> , Vol. 19, 1998, pages 415-423
		Leckie et al., "Novel therapy for COPD", <u>Exp. Opin. Invest. Drugs</u> , Vol. 9, No. 1, 2000, pages 3-23

EXAMINER	<i>Burnh K/L</i>	DATE CONSIDERED	<i>2/13/03</i>
----------	------------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.